Novartis, the Swiss pharmaceuticals group, yesterday offered minority shareholders in Alcon the equivalent of $11.2bn in stock to buy out their shares, lifting the total acquisition cost for the US eye care group to almost $50bn.
瑞士制药集团诺华制药(Novartis)昨日出价，以相当于112亿美元的股份，换购美国眼部护理集团爱尔康(Alcon)少数股东的股份，使收购总成本升至近500亿美元。
您已阅读14%（312字），剩余86%（1904字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。